Sign in

    Tyler Bussian

    Biotechnology Research Analyst at Brookline Capital

    Tyler Bussian, Ph.D., is a Biotechnology Research Analyst at Brookline Capital Markets, specializing in equity research within the biotechnology sector and covering companies such as Envoy Medical and CRVO. Notably, his most profitable rating yielded a 259.9% return, and he maintains a 3.40-star analyst rating on TipRanks, covering six stocks with a consistent record of strong performance. Dr. Bussian began his equity research career in 2010, held previous positions including Research Associate at the Mayo Clinic, and joined Brookline Capital in 2022. He holds a B.A. in Biology from DePauw University, a doctorate in Biochemistry and Molecular Biology from the Mayo Clinic Graduate School, and is recognized for scientific publications and achievements such as the Mayo Clinic Three Minute Thesis Championship.

    Tyler Bussian's questions to electroCore (ECOR) leadership

    Tyler Bussian's questions to electroCore (ECOR) leadership • Q4 2024

    Question

    Asked for an update on the Joerns Healthcare partnership for the managed care channel, noting its slower-than-expected start, and inquired about plans for that segment in 2025.

    Answer

    Management acknowledged the slower-than-hoped-for start but noted positive signs, or "green shoots," with over 30 repeating prescribers and a small but growing number of prescriptions being processed. They remain optimistic that momentum is building and will eventually reach a meaningful tipping point.

    Ask Fintool Equity Research AI